1. Home
  2. DCBO vs PRTA Comparison

DCBO vs PRTA Comparison

Compare DCBO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Docebo Inc.

DCBO

Docebo Inc.

HOLD

Current Price

$16.20

Market Cap

489.9M

Sector

N/A

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.81

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCBO
PRTA
Founded
2016
2012
Country
Canada
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
489.9M
539.9M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
DCBO
PRTA
Price
$16.20
$10.81
Analyst Decision
Buy
Buy
Analyst Count
9
9
Target Price
$32.00
$19.00
AVG Volume (30 Days)
100.0K
449.6K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$814,000.00
Revenue This Year
$12.89
$1,111.38
Revenue Next Year
$11.44
N/A
P/E Ratio
$22.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.39
$4.32
52 Week High
$33.69
$11.69

Technical Indicators

Market Signals
Indicator
DCBO
PRTA
Relative Strength Index (RSI) 41.90 67.15
Support Level N/A $9.69
Resistance Level $20.15 $10.90
Average True Range (ATR) 0.84 0.40
MACD -0.17 0.10
Stochastic Oscillator 42.96 96.87

Price Performance

Historical Comparison
DCBO
PRTA

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: